Deals
ADC Bio raises series D for continued development of cancer killing ADC tech
We were delighted to act for Downing LLP on its investment of VCT and EIS funds into ADC Biotechnology Limited, following on from Downing’s investment earlier in the year in what was ADC Bio’s series C (reported by HLaw here). This latest funding round for ADC Bio round raised £2.5 million in new equity finance.
Deal/project: Series D funding round
Date closed: October 2018
Space: Life sciences
Press releases:
Other lawyers and advisors: DWF (Frank Shepherd & team) acted for the company; Marriott Harrison advised Maven Capital; BioScience Managers also advised Downing LLP